HS
KPTI icon

HighVista Strategies’s Karyopharm Therapeutics KPTI Stock Holding History

HighVista Strategies’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,692
Closed -$1.13M – 121
2022
Q2 		$1.13M Buy
+16,692
New +$1.53M 0.68% 36

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

HighVista Strategies's KPTI Position: Q3 2022 in Review

HighVista Strategies sold out of Karyopharm Therapeutics (KPTI) in Q3 2022, closing a stake of 16,692 shares — an estimated $1.13M sold.

HighVista Strategies first reported a position in KPTI in Q2 2022 and held it in 1 quarter. The position peaked at $1.13M in Q2 2022. 147 funds tracked by Wall St. Rank hold KPTI as of Q3 2022.

  • HighVista Strategies reported no remaining Karyopharm Therapeutics position as of Q3 2022 after selling out during the quarter.
  • HighVista Strategies sold 16,692 Karyopharm Therapeutics shares in Q3 2022, an estimated $1.13M.
  • HighVista Strategies first reported a position in Karyopharm Therapeutics in Q2 2022 and held it in 1 quarter.
  • HighVista Strategies's Karyopharm Therapeutics position peaked at $1.13M in Q2 2022.
  • 147 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2022.

Based on HighVista Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.